FDA approves first drug for postpartum depression
The first drug for women suffering postpartum depression received federal approval on Tuesday, a move likely to pave the way for a wave of treatments to address a debilitating condition that is the most common complication of pregnancy.
The drug, a synthetic version of a naturally occurring hormone, may be a significant improvement over currently available antidepressants because it works very quickly, within 48 hours.
That may be especially helpful in circumstances where depression keeps mothers from providing their babies with the care, bonding and nurturing that is crucial for healthy development. Most antidepressants take two to four weeks to ease symptoms, if they work at all.
“Postpartum depression is a serious condition that, when severe, can be life-threatening,” Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products at the Food and Drug Administration’s Center for Drug Evaluation and Research, said in a statement.
“This approval marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option.”
There are limitations to the new drug, brexanolone, which will be marketed as Zulresso. It is delivered by infusion over 60 hours, during which a new mother must remain in a certified medical center, under supervision should she get dizzy or faint, as several patients did in clinical trials.
The infusion will be expensive, between $20,000 and $35,000, not including the costs of staying in the medical center for 2½ days.
A pill version, which would be much more accessible and easier for patients, is showing promise in its clinical trials and would be submitted for approval in a couple of years if the results are good, according to the manufacturer, Sage Therapeutics.
The infusion is to be administered just once, and patients may also take standard antidepressants. Company officials say they expect that insurers will cover the treatment; insurers said this week that they are evaluating the drug.
Clinical trials of the drug, all sponsored by Sage, found that it produced a steeper decrease in symptoms in women with severe and moderate postpartum depression than a similar placebo infusion.
The relief from depression continued for a month after the treatment. While there were anecdotal reports that it extended beyond that period for some women, there has not been systematic research on longer-term results.
“The major thing is, of course, the rapid effect,” said Dr. Margaret Spinelli, a clinical professor of psychiatry at Columbia University, who treats and studies postpartum depression and was not involved in the research on brexanolone.
“That it’s the first that’s designed for postpartum depression is important and means it will probably be a segue to design other medications for postpartum depression to be administered in an easier way,” she added.
The treatment may be helpful for up to 30 percent of the 400,000 American women who develop postpartum depression each year, said Dr. Kimberly Yonkers, a professor of psychiatry, obstetrics-gynecology and reproductive sciences at Yale, who was not involved in the research.
Candidates for treatment would likely be those experiencing severe symptoms or who failed to improve on standard antidepressants, Yonkers said.
“This brings up a lot of very complex public health issues,” she added, noting the expense of the treatment and the need for patients to be admitted to medical centers.
“It may be worth it, if somebody has been treatment-resistant or they can’t wait the two to four weeks for an antidepressant to kick in,” Yonkers said. “Depression can be pretty miserable,” she added, harming the entire family.
Stephanie Hathaway, 33, a mother of two in South Windsor, Conn., had no history of depression. But after giving birth to her daughters – Hadley, 4, and Brenley, 2 – she began crying nonstop, and lost interest in doing things she loved, like cooking and socializing.
“I starting having intrusive thoughts that would not go away,” she recalled. “‘Your daughter deserves a better mom, and your husband deserves a better wife’ – that would just play on repeat.”
Ultimately Hathaway felt suicidal and feared she would harm herself if she stopped holding the baby. After Hadley’s birth, Hathaway, then living with her husband in China, spent two weeks under round-the-clock suicide watch at home.
The antidepressant she was prescribed, Zoloft, took three months, at increasing dosages, to eliminate her symptoms. Following Brenley’s birth, Zoloft didn’t help at all, Hathaway said, so about five months afterward, she volunteered for the brexanolone trial.
Between 12 and 18 hours after the infusion started, “I actually woke up from a nap and those intrusive thoughts that played on repeat, they were gone,” Hathaway said.
After leaving the hospital, “I felt like myself again,” Hathaway said. “I’m not going to say I was 100 percent, but I will say there was so much less of a gap to get there.”
She did not stop antidepressants altogether, but switched to a low dose of Effexor.
Dizziness and sleepiness were the most common side effects in the trials, each affecting about 1 in 8 patients, including Hathaway. The most worrisome effect, the FDA said, was fainting or temporary loss of consciousness, seen in five patients. All recovered within an hour and resumed getting the infusion.
Brexanolone is a synthetic form of allopregnanolone, a hormone produced by progesterone in the brain that may help ease depression and anxiety by dampening neural activity, said Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the University of North Carolina at Chapel Hill, who was the principal investigator for the brexanolone studies.
The research presented to the FDA consisted of three clinical trials that were led by Meltzer-Brody and funded by Sage Therapeutics, which was also involved in the study design, data analysis, interpretation and writing of the reports.
The trials involved 247 women randomly selected to receive a placebo or brexanolone – a relatively small number of participants, compared to many other medical trials.
They were asked to stop breast-feeding during the infusion and for a few days after. But Meltzer-Brody said the drug appears safe for nursing mothers and babies, because very little of it seeps into breast milk.
Depression improved in the women receiving brexanolone and in those receiving placebo, a phenomenon common in studies of depression treatments. But more women in the brexanolone group showed improvement, and their improvement was more substantial.
Stephanie Hathaway with her daughters Brenley, left, and Hadley, in South Windsor, Conn. After the birth of her youngest daughter, Hathaway volunteered for a clinical trial for the first drug for women suffering postpartum depression.